Dianthus Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.38 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $88.32Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $4.9B Enterprise Value $4.8B Shares Outstanding 54.9M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Dianthus Therapeutics is a highly capitalized, clinical-stage biotechnology company developing claseprubart (DNTH103), a potentially best-in-class subcutaneous monoclonal antibody targeting active C1s in the classical complement pathway. Following an upsized public offering in March 2026, the company boasts a cash runway extending into 2030, significantly reducing near-to-mid-term financing risk. While Sanofi's recent Phase 3 failure of its rival C1s inhibitor riliprubart in CIDP has introduced class-level uncertainty, Dianthus's positive Phase 2 MaGic data in generalized Myasthenia Gravis (gMG) and a robust 75% interim responder rate in the CAPTIVATE Part A trial support a highly differentiated, potent, and convenient therapeutic profile. The stock represents a compelling high-risk, high-reward opportunity with multiple near-term clinical catalysts. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$109.00 Mean target$137.62 High · most bullish analyst$200.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $109.0015% Claseprubart fails to replicate its Phase 2 efficacy in the Phase 3 gMG trial, or safety concerns emerge. The CIDP program is discontinued or severely delayed due to lack of efficacy, mirroring Sanofi's riliprubart failure. The pipeline-in-a-product thesis invalidates, driving the stock down to its cash floor. Base CaseCentral scenario $137.6260% Matches the consensus meanClaseprubart successfully initiates and advances its Phase 3 gMG trial, supported by its FDA Orphan Drug Designation. The Phase 2 MMN trial meets its primary safety and tolerability endpoints with positive efficacy trends. The company refines its CIDP strategy with regulatory alignment, maintaining its robust cash runway into 2030 while clinical programs mature. Bull CaseUpside scenario $200.0025% Claseprubart achieves best-in-class status in gMG with its convenient 300mg Q2W/Q4W subcutaneous self-administration, capturing significant market share from entrenched IV therapies. The Phase 3 CAPTIVATE trial in CIDP overcomes class-level doubts with a positive Part B readout, and the Phase 2 MoMeNtum trial in MMN delivers strong proof-of-concept data, establishing a dominant neuromuscular franchise. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |